Brookline, headquartered Edgewood Oncology, a clinical-stage biotechnology firm specializing in administering BTX-A51 to individuals with hematologic malignancies and genetically-specific solid tumours, has secured $20 million in Series A financing. Edgewood Oncology is a clinical-stage biotechnology company advancing BTX-A51 for patients with hematologic malignancies and genetically-defined solid tumours
Alta Partners spearheaded this funding round.
The infusion of capital will fuel the progression of BTX-A51’s clinical development in acute myeloid leukaemia (AML) and propel the precision medicine initiatives targeting breast cancer within the company.
[Sign up here to never miss these candid conversations delivered straight to your inbox.]
